Dose-Dependent Effects of FKRP Gene-Replacement Therapy on Functional Rescue and Longevity in Dystrophic Mice

Charles Harvey Vannoy1, Victoria Leroy1, Qi Long Lu1

  • 1McColl-Lockwood Laboratory for Muscular Dystrophy Research, Carolinas Medical Center, Atrium Health, Charlotte, NC 28203, USA.

Insights

FKRP gene-replacement therapy shows promise for muscular dystrophy-dystroglycanopathies (MDDGs). This study in FKRP-mutant mice demonstrated dose-dependent restoration of biochemical defects and improved lifespan, supporting clinical trials.

Area of Science:

  • Genetics and Molecular Biology
  • Neurology
  • Regenerative Medicine

Background:

  • Muscular dystrophy-dystroglycanopathies (MDDGs) caused by FKRP gene mutations present a spectrum of severity with limited treatment options.
  • FKRP-related disorders lack a cure, necessitating exploration of novel therapeutic strategies for symptom management and disease modification.

Purpose of the Study:

  • To evaluate the safety and therapeutic potential of FKRP gene-replacement therapy using an AAV9 vector in a mouse model of FKRP-related MDDG.
  • To assess the longitudinal effects of dose-escalation gene therapy on biochemical, histopathological, functional, and lifespan outcomes.

Main Methods:

  • Systemic administration of AAV9-FKRP to FKRP P448L mice at 5 weeks of age.
  • Comprehensive analysis of protein/gene expression, histopathology, skeletal muscle, and cardiorespiratory function over 9 and 52 weeks.
  • Lifespan assessment in an advanced disease stage model.

Main Results:

  • FKRP gene-replacement therapy restored biochemical defects in a dose-dependent manner.
  • Treatment showed potential for improving disease progression trajectory and extending lifespan.
  • Histopathological and functional improvements were observed, supporting therapeutic efficacy.

Conclusions:

  • Early-stage FKRP gene-replacement therapy is safe and therapeutically beneficial in a mouse model of FKRP-related MDDG.
  • Dose-dependent restoration of FKRP function offers a promising avenue for treating these rare neuromuscular disorders.
  • These findings provide a strong rationale for initiating clinical trials in patients with FKRP-related disorders.

Related Concept Videos

Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.6K
Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
1.0K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
779
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
675
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy01:26

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in...
217
Biological Effects of Radiation02:59

Biological Effects of Radiation

All radioactive nuclides emit high-energy particles or electromagnetic waves. When this radiation encounters living cells, it can cause heating, break chemical bonds, or ionize molecules. The most serious biological damage results when these radioactive emissions fragment or ionize molecules. For example, α and β particles emitted from nuclear decay reactions possess much higher energies than ordinary chemical bond energies. When these particles strike and penetrate matter, they...
17.9K